I’d buy this FTSE 100 stock without hesitation

Finding the right investments can be a challenge, but I’ve found one FTSE 100 stock that ticks all the boxes for my long-term portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In today’s volatile market, finding reliable stocks that offer both stability and growth can be challenging. However, there are plenty of FTSE 100 stocks that stand out to me as compelling investments. Here’s one I’d buy at the next opportunity.

AstraZeneca

AstraZeneca (LSE:AZN), the biopharmaceutical giant, is my first pick in the FTSE 100. With a market cap of £191.4bn, it’s a heavyweight in the pharmaceuticals industry, focusing on discovering, developing, and commercialising prescription medicines.

According to a discounted cash flow (DCF) calculation, the firm is currently trading at a staggering 34.9% below its estimated fair value. Of course, this isn’t a guarantee of value, but definitely shows potential.

Should you invest £1,000 in Royal Mail Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Royal Mail Group made the list?

See the 6 stocks

The company’s future looks bright. Analysts forecast annual earnings growth of about 15% over the coming few years, indicating strong potential for capital appreciation. This growth isn’t just speculative. Earnings grew by an impressive 34.6% over the past year, demonstrating its ability to deliver robust financial results.

Ticking the final box for me, AstraZeneca offers a reliable dividend yield of 2%. Although not the highest in the market, the company’s payout ratio of 71% suggests the dividend is sustainable, especially considering its strong earnings growth.

Product line-up

The company’s success is underpinned by its robust product line-up. Key drugs like Tagrisso, Imfinzi, and Lynparza in oncology, Farxiga in diabetes, and Breztri in respiratory diseases are driving revenue growth. By building a strategic focus on high-growth areas like oncology and rare diseases positions, the business appears well positioned for the future.

During the pandemic, AstraZeneca gained global recognition for its Vaxzevria Covid vaccine. But its story doesn’t end there. Recent updates show continued innovation, such as positive results from the Phase III trial of Sipavibart, a long-acting antibody for preventing Covid in immunocompromised patients. This demonstrates AstraZeneca’s adaptability and commitment to addressing urgent medical needs, which may set it apart from other companies in the sector.

Risks

Of course it’s not all good news. There’s also a huge amount of competition to consider here. With many companies racing to approval for new products, problems in development can have enormous repercussions.

The financials also show some areas of concern, such as a high level of debt, but for me it’s essential to view this in the right context. High debt is never good, but it’s also common in the pharmaceutical industry, where companies invest heavily in R&D to develop new, potentially blockbuster drugs.

The price-to-earnings (P/E) ratio of the company at 39.2 times is also pretty high, and significantly above the average of the sector at 25.7 times. With plenty of future earnings seemingly in the share price already, any disappointment could lead to a major sell-off.

Overall

In summary, AstraZeneca offers a compelling mix of undervaluation, strong growth prospects, stable dividends, and a robust product portfolio. Despite some financial concerns, its strategic focus and proven ability to deliver make it a FTSE 100 stock I’d buy without hesitation. When I next have cash available, I’ll be picking up as many shares as I can.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Gordon Best has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6.8% dividend yield! Consider these 2 ‘secret’ passive income stocks to target a £1,360 payday in 2025

Looking for ways to generate above-average dividend income? These lesser-bought income stocks are worth a close look.

Read more »

Elevated view over city of London skyline
Investing Articles

The M&G dividend yields over 10% — and could get higher!

Christopher Ruane explains why he's upbeat about the long-term outlook for the M&G dividend yield and would happily buy the…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

2 popular UK growth stocks I wouldn’t touch with a bargepole in today’s market

Buying growth stocks can deliver market-beating returns, but this FTSE 250 pair doesn't look like a convincing investment for our…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

10 FTSE shares falling today after President Trump’s tariffs bombshell!

Our writer explains why JD Sports Fashion from the FTSE 100 and a diverse bunch of other UK stocks are…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With value investing back in vogue, I’m taking a leaf out of Warren Buffett’s playbook

With tariffs and trade wars resulting in heightened market volatility, Andrew Mackie takes comfort in Warren Buffett’s words of wisdom.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Around a 1-year high, is there enough value left in Next’s share price to make it worth me buying?

Next’s share price has risen a lot in eight months, but there could still be a lot of value left…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

OMG DYOR but IMO this ‘cool’ FTSE 100 stock offers bangin’ VFM!

Despite being one of the least trendy 50-somethings around, our writer considers how Gen Z could help push this FTSE…

Read more »

Investing Articles

2 cheap FTSE 100 and FTSE 250 growth stocks to consider as stock markets sink

I think these Footsie and FTSE 250 growth shares could be very shrewd buys to consider in the current climate.…

Read more »